Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Two-dose
100%
Clinical Response
100%
Antibody Inhibition
100%
Hemagglutination
100%
Plasma Cell Disorders
100%
High-dose Influenza Vaccine
100%
Serological Response
100%
Single-arm Trial
100%
Vaccination Strategy
80%
Virus
60%
High Dose
60%
Influenza Vaccination
60%
2-dose
60%
Seroprotection
60%
Multiple Myeloma
40%
Influenza
40%
Trivalent Influenza Vaccine
40%
Well Tolerated
40%
Laboratory-confirmed Influenza
40%
Influenza Infection
40%
Risk Factors
20%
Adverse Events
20%
Partial Response
20%
Existing Data
20%
Clinical Correlation
20%
Conventional Chemotherapy
20%
Protease Inhibitors
20%
Titer
20%
Logistic Regression Model
20%
Disease Response
20%
Randomized Controlled Study
20%
Response Assessment
20%
Seasonal Influenza Vaccination
20%
Massachusetts
20%
Influenza Vaccine
20%
2009 H1N1
20%
Influenza Season
20%
Vaccine Strain
20%
Texas
20%
Plasma Cell Dyscrasia
20%
Active Therapy
20%
Booster Dose
20%
A(H1N1)pdm09
20%
H3N2
20%
Immunomodulatory Drugs (IMiDs)
20%
Seroprotection Rate
20%
Medicine and Dentistry
Drug Megadose
100%
Arm
100%
Immunoglobulin Producing Cell
100%
Influenza Vaccine
100%
Hemagglutination Inhibiting Antibody
100%
Influenza Vaccination
80%
Influenza
80%
Virus
60%
Multiple Myeloma
40%
Diseases
40%
Logistic Regression Analysis
20%
Retrospective Study
20%
Morbidity
20%
Seasonal Influenza
20%
Influenza A Virus (H1N1)
20%
Immunomodulatory Drug
20%
Proteasome Inhibitor
20%
Plasma Cell Dyscrasia
20%
Vaccine Strain
20%
Booster Dose
20%
Influenza A Virus (H3N2)
20%
Chemotherapy
20%
Adverse Event
20%
Immunology and Microbiology
Arm
100%
Drug Megadose
100%
Immunoglobulin Producing Cell
100%
Influenza
100%
Influenza Vaccine
100%
Hemagglutination Inhibiting Antibody
50%
Virus
30%
Infectious Disease
20%
Multiple Myeloma
20%
Infection
20%
Proteasome
10%
Morbidity
10%
Titer
10%
Influenza A Virus (H1N1)
10%
Immunomodulatory Drug
10%
Influenza A Virus (H3N2)
10%
Plasma Cell Dyscrasia
10%
Pharmacology, Toxicology and Pharmaceutical Science
Live Attenuated Influenza Vaccine
100%
Influenza
100%
Vaccination
100%
Hemagglutination Inhibiting Antibody
71%
Virus
42%
Multiple Myeloma
28%
Diseases
28%
Adverse Event
14%
Retrospective Study
14%
Morbidity
14%
Chemotherapy Regimens
14%
Seasonal Influenza
14%
Influenza A Virus (H1N1)
14%
Proteasome Inhibitor
14%
Vaccine Strain
14%
Influenza A Virus (H3N2)
14%
Plasma Cell Dyscrasia
14%